Cramer listened to a lot of conference calls this week, and here are some of his picks.
TheStreet's Jim Cramer says that the biotech space is likely to continue its move higher, as earnings come in stronger-than-expected.
Edwards Lifesciences (EW) shares are climbing after the company beat analysts third quarter earnings expectations and raised its full year guidance.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Wednesday was a strong session for a number of stocks, and here are three, in particular, to watch for more upside.
Eli Lilly lost exclusivity in high profile drugs like Cymbalta and Evista and generic competition brought down the volume of medications doctors prescribed.
Eli Lilly (LLY) reported third quarter earnings below analysts expectations while revenues exceeded forecasts.
Alcobra disclose new details about the phase III study of attention-deficit hyperactivity disorder drug candidate which contradict results announced by the company in an Oct. 6 press release.
U.S. stocks move lower in midday trading on Wednesday on higher than forecast oil inventories released by the Energy Information Administration.
Biogen Idec (BIIB) shares are declining after the company confirmed the death of a patient using its multiple sclerosis treatment.
Intuitive Surgical (ISRG) shares are down despite beating analysts third quarter revenue and earnings guidance.
But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.
Thermo Fisher Scientific (TMO) shares are dropping after the company lowered its full year revenue and earnings guidance on Wednesday.
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
Amgen (AMGN) shares are climbing after an activist hedge fund manager Dan Loeb released a positive letter to investors.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV